Generic drugs

Global Generic Drugs Market Report 2022: Market Reached High

Dublin, March 30, 2022 (GLOBE NEWSWIRE) — The report “Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunities and Forecasts 2022-2027” has been added to from offer.

The global generic drugs market reached a value of US$320 billion in 2021. Going forward, the market is expected to reach US$482.5 billion by 2027 growing at a CAGR of 7% in 2022-2027 .

Keeping in mind the uncertainties of COVID-19, we continuously monitor and assess the direct and indirect influence of the pandemic. This information is included in the report as a major market contributor.

A generic drug is a drug that contains the same active ingredient and has an equivalent therapeutic effect as the brand name drug. It is also identical in terms of safety, quality, dosage, strength, route of administration, intended use, effect, form, quality, and side effects.

These drugs can only be produced after the brand name drug’s patent expires. Compared to branded drugs, the production of generics is much cheaper because it does not require repeated clinical (human) and animal studies to demonstrate the effectiveness and safety of the drug. Due to a reduction in the initial cost of research, generics are generally sold at a significantly lower price in the market.

Market trends:

Due to the aging of the population and the increasing incidence of chronic diseases, governments in developed countries have made efforts to reduce health care costs by encouraging the production of generics. While, in developing countries, affordability and accessibility are some of the major issues facing the healthcare sector.

To address these issues, governments and other regulatory bodies have encouraged manufacturers to introduce effective generic drugs. However, despite the rapid expiration of patents on branded drugs, there has been a shortage of generics. This situation is currently being corrected by various initiatives taken by hospitals, institutions and other organizations around the world.

For example, in 2018, a coalition of seven hospitals and three philanthropic organizations in the United States announced that they would tackle drug shortages and the high cost of essential drugs by launching a generic drug company, named Civica Rx. . The company produces 14 FDA-approved drugs available on the market since the start of 2019.

Apart from this, in 2018, the United States Food and Drug Administration (USFDA) created policies to make the market entry and generic approval process more efficient. It has published guidance documents for the development of hard-to-copy drug classes and specific complex drugs.

Key Market Segmentation:

  • Central nervous system diseases are currently the leading therapeutic area, accounting for the majority of the total market.
  • Currently, oral medications are the most preferred product, due to the convenience attached to their administration, which requires little or no medical assistance.
  • Currently, the majority of generics are distributed through retail pharmacies, as most generic drugs are over-the-counter drugs that can be purchased without a prescription.
  • On a regional basis, the United States accounts for the largest market, accounting for the largest market share. This growth is driven by numerous US government initiatives aimed at improving manufacturing and access to generic drugs in the country.

Competitive Landscape:

The market is fragmented in nature with the presence of various small and large manufacturers.

Some of the major players operating in the market include

  • Teva Pharmaceuticals Industries Ltd.
  • Mylan AG
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius SE & Co.
  • Lupine Limited
  • Endo Pharmaceuticals Inc.
  • Aurobindo Pharma Limited
  • Aspen Pharmacare Holdings Limited.

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive Summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Global Generic Drug Industry
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakdown by Country
5.5 Market Breakdown by Therapeutic Area
5.6 Market Breakdown by Drug Delivery
5.7 Market Breakdown by Distribution Channel
5.8 Market Forecast
5.9 SWOT analysis
5.10 Value chain analysis
5.11 Porter’s Five Forces Analysis
5.12 Regulation in the generic industry
5.13 Key Market Drivers and Success Factors

6 Performance of key countries
6.1 United States
6.2 China
6.3 Brazil
6.4 Germany
6.6 India
6.7 United Kingdom
6.8 Japan
6.9 Canada
6.10 Italy

7 Market Breakdown by Therapeutic Area
7.1 Central nervous system
7.2 Cardiovascular
7.3 Dermatology
7.4 Genitourinary/Hormonal
7.5 Respiratory
7.6 Rheumatology
7.7 Diabetes
7.8 Oncology

8 Market Breakdown by Drug Delivery
8.1 Oral
8.2 Injectables
8.3 Dermal/Topical
8.4 Inhalers

9 Market Breakdown by Distribution Channel
9.1 Retail pharmacies
9.2 Hospital pharmacies

10 Competitive Landscape
10.1 Market structure
10.2 Market Breakdown by Major Players
10.3 Key Player Profiles

11 Generic drug manufacturing process
11.1 Product Overview
11.2 Detailed process flow (tablets)
11.3 Detailed process flow (injectable)
11.4 Various types of unit operations involved
11.5 Mass balance and raw material requirements

12 Project details, requirements and costs involved
12.1 Land Requirements and Expenditures
12.2 Construction Requirements and Expenses
12.3 Plant machinery
12.4 Images of machines
12.5 Raw Material Requirements and Expenditures
12.6 Packaging Requirements and Expenses
12.7 Transportation Requirements and Expenses
12.8 Utility Requirements and Expenses
12.9 Labor Requirements and Expenditures
12.10 Other capital investments

13 Loans and Financial Assistance

14 Economics of the project
14.1 Capital cost of the project
14.2 Technical and economic parameters
14.3 Product Pricing and Margins at Different Levels of the Supply Chain
14.4 Taxation and depreciation
14.5 Revenue projections
14.6 Expenditure Projections
14.7 Financial Analysis
14.8 Profit Analysis

For more information about this report visit

  • Global Generic Drugs Market

Joan J. Dean

The author Joan J. Dean